Global Rabies Immune Globulin Market Size, Share and Trends Analysis Report, By Type (HRIG and ERIG), Forecast (2022-2028)

The rabies immune globulin (RIG) market is anticipated to grow at a significant CAGR of 3.8% during the forecast period (2022-2028). RIG is a hyperimmune globulin made from persons who have been inoculated against rabies and have extremely high antibody titers. The RIG is used to treat people who have been exposed to rabid animals. The major factor driving the growth of the market is the rising prevalence of rabies globally. According to the World Health Organization (WHO), Rabies is a viral illness that may be prevented by vaccination and is found in over 150 nations and territories. Dogs are the primary cause of human rabies mortality, accounting for up to 99% of all human rabies transmissions. Interrupting transmission can be accomplished by vaccinating dogs and avoiding dog bites. Every year, the illness kills tens of thousands of people, mostly in Asia and Africa.

The global rabies immune globulin market is segmented based on type. Based on type, the market is sub-segmented into HRIG and ERIG. Among these segments, the HRIG segment is expected to propel the growth of the market due to its high efficiency in neutralizing the rabies virus as compared to ERIG. When the HRIG is not available, then ERIG can also be used to neutralize the rabies virus.

The market players are also contributing significantly to the market growth by adopting various strategies, including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in April 2020, Grifols announced the launch of a new 3-mL (900-IU) vial for HyperRAB (rabies immune globulin [human]), a treatment for rabies postexposure prophylaxis. The addition of a 3-mL (900-IU) option will now give healthcare providers greater convenience by potentially reducing the number of vials used during administration – cutting down on product and packaging waste in the process. The new vial size will also provide storage efficiencies for hospital pharmacies by decreasing the number of smaller vials they currently have to keep in stock. HyperRAB 3-mL (900-IU) was approved by the US Food and Drug Administration (FDA) in November 2019, broadening the company’s current HyperRAB portfolio, which presently includes 300 IU/mL potency supplied in 1-mL (300-IU) and 5-mL (1500-IU) vials.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-CSL Behring, Grifols SA, Sanofi SA, and Sun Pharmaceuticals Co. Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Rabies Immune Globulin Market Report by Segment

By Type

• HRIG
• ERIG

Global Rabies Immune Globulin Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa